BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

PrimeraDx Appoints Jeff Liter as VP of Corporate Development


10/13/2011 12:02:49 PM

MANSFIELD, Mass., Oct. 13, 2011 /PRNewswire/ -- PrimeraDx today announced that Jeff Liter has been appointed as the Vice President of Corporate Development.

"Jeff's diverse background in all aspects of corporate development makes him a great addition to the leadership team," Said Matt McManus, President and CEO, PrimeraDx. "PrimeraDx's strategy is to leverage the multimodal capabilities of the ICEPlex system in the MDx market and define a model for the next generation of molecular diagnostics. Jeff has a great deal of experience that will help bring scale to our commercial efforts."

Mr. Liter has more than 20 years of experience in business development, sales, corporate finance and operations. Prior to joining PrimeraDx, he was the Director of Strategy, Business Development, & Licensing for Beckman Coulter, where he was responsible for Business Development of the Immunoassay and Molecular Diagnostics Groups. Jeff also was the managing director with On Point Consulting, focusing on Post Acquisition Integration Support and Transactional Advisory Services. Specifically, he delivered integration services to Onyx Pharmaceuticals and established a Knowledge Transfer Program within the first 3 months of a critical integration. He received his MBA from University of Minnesota and his BA from Illinois State University.

"The ICEPlex platform is already creating a stir in the MDx community, with the ability to assay mRNAs, microRNAs and SNPs in the same well, from a single sample," Commented Mr. Liter. "I am excited to work with Matt and the team, to develop the company's customer base and strategic alliances."

About PrimeraDx

PrimeraDx is dedicated to the high growth field of molecular diagnostics. The Company has developed a unique platform for high-multiplex, quantitative, real-time PCR based on its proprietary STAR technology, implemented on the walk-away ICEPlex® instrument system. PrimeraDx is developing a broad range of applications in oncology, infectious disease, companion diagnostics and multiple non-clinical molecular markets, both through its own efforts and in collaboration with partners. The Company is backed by a strong group of experienced venture-capital investors, including Abingworth, InterWest Partners, CHL Medical Partners, and Malaysia Technology Development Corporation. The Company's website is: www.primeradx.com or www.multiplexpcr.com.

CONTACT: Andrew Bond, +1-508-618-2752, abond@primeradx.com

SOURCE PrimeraDx



Read at BioSpace.com

PrimeraDx
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->